Verition Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $629K | Sell |
1,409
-6,997
| -83% | -$3.26M | ﹤0.01% | 1505 |
|
|
2025
Q4 | $3.81M | Sell |
8,406
-3,138
| -27% | -$1.35M | 0.02% | 1081 |
|
|
2025
Q3 | $4.52M | Sell |
11,544
-11,698
| -50% | -$4.89M | 0.02% | 1255 |
|
|
2025
Q2 | $10.3M | Buy |
23,242
+9,990
| +75% | +$4.6M | 0.05% | 513 |
|
|
2025
Q1 | $6.42M | Sell |
13,252
-5,578
| -30% | -$2.6M | 0.03% | 677 |
|
|
2024
Q4 | $7.58M | Buy |
18,830
+5,730
| +44% | +$2.66M | 0.03% | 656 |
|
|
2024
Q3 | $6.09M | Buy |
13,100
+4,379
| +50% | +$2.1M | 0.03% | 722 |
|
|
2024
Q2 | $4.09M | Sell |
8,721
-11,804
| -58% | -$5.12M | 0.02% | 842 |
|
|
2024
Q1 | $8.58M | Buy |
20,525
+10,380
| +102% | +$4.39M | 0.06% | 385 |
|
|
2023
Q4 | $4.13M | Buy |
10,145
+7,381
| +267% | +$2.73M | 0.03% | 513 |
|
|
2023
Q3 | $961K | Buy |
2,764
+800
| +41% | +$280K | 0.01% | 1103 |
|
|
2023
Q2 | $691K | Hold |
1,964
| – | – | 0.01% | 1065 |
|
|
2023
Q1 | $619K | Sell |
1,964
-33,722
| -94% | -$10.1M | 0.01% | 1129 |
|
|
2022
Q4 | $10.3M | Sell |
35,686
-21,728
| -38% | -$6.62M | 0.16% | 146 |
|
|
2022
Q3 | $16.6M | Buy |
57,414
+20,821
| +57% | +$5.99M | 0.19% | 112 |
|
|
2022
Q2 | $10.3M | Buy |
+36,593
| New | +$9.79M | 0.2% | 89 |
|
|
2022
Q1 | – | Sell |
-5,252
| Closed | -$1.25M | – | 3056 |
|
|
2021
Q4 | $1.15M | Sell |
5,252
-12,458
| -70% | -$2.42M | 0.01% | 1200 |
|
|
2021
Q3 | $3.21M | Buy |
17,710
+13,590
| +330% | +$2.65M | 0.03% | 407 |
|
|
2021
Q2 | $831K | Buy |
4,120
+1,888
| +85% | +$395K | 0.01% | 878 |
|
|
2021
Q1 | $480K | Buy |
2,232
+1,348
| +152% | +$296K | 0.01% | 891 |
|
|
2020
Q4 | $209K | Sell |
884
-269
| -23% | -$61.7K | ﹤0.01% | 950 |
|
|
2020
Q3 | $314K | Buy |
+1,153
| New | +$318K | 0.01% | 766 |
|
|
2020
Q1 | – | Sell |
-8,049
| Closed | -$1.76M | – | 1081 |
|
|
2019
Q4 | $1.76M | Buy |
8,049
+5,148
| +177% | +$1.04M | 0.03% | 288 |
|
|
2019
Q3 | $491K | Sell |
2,901
-943
| -25% | -$167K | 0.01% | 634 |
|
|
2019
Q2 | $705K | Buy |
+3,844
| New | +$672K | 0.02% | 549 |
|
|
2018
Q3 | – | Sell |
-7,893
| Closed | -$1.34M | – | 1456 |
|
|
2018
Q2 | $1.34M | Buy |
+7,893
| New | +$1.22M | 0.08% | 300 |
|
|
2017
Q4 | – | Sell |
-2,952
| Closed | -$449K | – | 1261 |
|
|
2017
Q3 | $449K | Sell |
2,952
-741
| -20% | -$112K | 0.04% | 637 |
|
|
2017
Q2 | $476K | Buy |
3,693
+287
| +8% | +$34.5K | 0.05% | 443 |
|
|
2017
Q1 | $372K | Buy |
+3,406
| New | +$300K | 0.03% | 738 |
|
|
2016
Q3 | – | Sell |
-2,388
| Closed | -$205K | – | 1322 |
|
|
2016
Q2 | $205K | Sell |
2,388
-11,946
| -83% | -$1.03M | 0.03% | 759 |
|
|
2016
Q1 | $1.14M | Buy |
+14,334
| New | +$1.3M | 0.18% | 113 |
|
|
2015
Q4 | – | Sell |
-2,525
| Closed | -$263K | – | 614 |
|
|
2015
Q3 | $263K | Buy |
2,525
+840
| +50% | +$108K | 0.07% | 383 |
|
|
2015
Q2 | $208K | Sell |
1,685
-178
| -10% | -$22.4K | 0.04% | 462 |
|
|
2015
Q1 | $220K | Buy |
+1,863
| New | +$223K | 0.03% | 291 |
|
|
2014
Q4 | – | Sell |
-2,657
| Closed | -$298K | – | 673 |
|
|
2014
Q3 | $298K | Buy |
+2,657
| New | +$253K | 0.04% | 397 |
|
Other funds holding VRTX
VCM
VPM
Verition Fund Management's VRTX Position: Q1 2026 in Review
Verition Fund Management reduced its Vertex Pharmaceuticals (VRTX) stake by 83% in Q1 2026, selling an estimated $3.26M and leaving 1,409 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #1505.
Verition Fund Management first reported a position in VRTX in Q3 2014 and has held it in 35 quarters since. The position peaked at $16.6M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Verition Fund Management held 1,409 shares of Vertex Pharmaceuticals worth $629K as of Q1 2026.
- Verition Fund Management sold 6,997 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.26M.
- Vertex Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1505 holding.
- Verition Fund Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 35 quarters since.
- Verition Fund Management's Vertex Pharmaceuticals position peaked at $16.6M in Q3 2022.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.